secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001837607-24-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma secures $15M convertible note from Daewoong and aligns with FDA on Phase 3 migraine trial design
--------------------------------------------------------------------------------

- Issues up to $15M senior secured convertible notes to Daewoong; first $5M tranche closes within 10 days, second $10M subject to license amendment.
- Terminates forward purchase agreements with ACM and Polar; retains ~3.1M shares each, up to $1.5M liquidated damages for registration failures.
- FDA confirms primary endpoint (change in mean monthly migraine days over weeks 13-24) for Phase 3 episodic and chronic migraine programs.
- Interim analysis of ongoing Phase 2 chronic migraine study now planned; data expected Q2 2024, complete top-line data on track for Q3 2024.
- ABP-450 Phase 2 chronic migraine study enrolled 492 patients; will use patented injection paradigm with fewer injections than current treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/aeon-20240318x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer